Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen s Revenues Nearly Double in Q3

NEW YORK, Nov. 3 (GenomeWeb News) - Nanogen posted a near doubling of revenue in the third quarter, the company said yesterday.  

 

Nanogen's total revenues for the period ended Sept. 30 increased 191 percent to $3.2 million from $1.1 million in the comparable quarter last year, the company said. Nanogen reported $1.1 million in product revenue for the third quarter of 2005, compared to $671,000 during the same period in 2004.

 

R&D spending in the period increased 26.7 percent to $5.7 million from $4.5 million year over year.

 

Nanogen's net loss fell to $8.8 million, or $0.18, from $9.4 million, or $.28 per share year over year.

 

The company had cash, equivalents, and short-term investments totaling $40.7 million at the end of the recent quarter.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.